TCWA
SYRS

Ten Capital Wealth Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Ten Capital Wealth Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-219
Closed -$585 – 563
2023
Q1 		$585 Hold
219
– – ﹤0.01% 499
2022
Q4 		$786 Hold
219
– – ﹤0.01% 496
2022
Q3 		$1K Buy
+219
New +$1.78K ﹤0.01% 548

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Ten Capital Wealth Advisors's SYRS Position: Q2 2023 in Review

Ten Capital Wealth Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2023, closing a stake of 219 shares — an estimated $585 sold.

Ten Capital Wealth Advisors first reported a position in SYRS in Q3 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 53 funds tracked by Wall St. Rank hold SYRS as of Q2 2023.

  • Ten Capital Wealth Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Ten Capital Wealth Advisors sold 219 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $585.
  • Ten Capital Wealth Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Ten Capital Wealth Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1K in Q3 2022.
  • 53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Ten Capital Wealth Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.